Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Gynaecological Clear Cell Cancer
NCT03425565Phase 2Completed
- Sponsor
- University College London
- Start
- Feb 2019
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in clear cell carcinoma (CCC), sponsored by University College London. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
clear cell carcinoma (CCC)
Beyond the preview
Go deeper on NCT03425565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425565.